RSRangappa Kanchugarakoppal Subbegowda

Rangappa Kanchugarakoppal Subbegowda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rangappa Kanchugarakoppal Subbegowda has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of a New Arylamination Reaction Catalyzed by Polymer Bound 1,3-(Bisbenzimidazolyl) Benzene Co(II) Complex and Generation of Bioactive Adamanate Amines

    by Baburajeev Chumadathil Pookunoth, Shilpa Eshwar Rao, Suresha Nayakanahundi Deveshegowda, Prashant Kashinath Metri, Kashifa Fazl-Ur-Rahman, Ganga Periyasamy, Gayathri Virupaiah, Babu Shubha Priya, Vijay Pandey, Peter E. Lobie, et al.

    We herein report the preparation and characterization of an inexpensive polymer supported 1,3-bis(benzimidazolyl)benzeneCo(II) complex [PS-Co(BBZN)Cl2] as a catalyst by using the polymer (divinylbenzene cross-linked chloromethylated polystyrene), on which 1,3-bis(benzimidazolyl)benzeneCo(II) complex (PS-Co(BBZN)Cl2) has been immobilized. This catalyst was employed to develop arylamination reaction and robustness of the same reaction was demonstrated by synthesizing various bioactive adamantanyl-tethered-biphenylamines. Our synthetic methodology was much improved than reported methods due to the use of an inexpensive and recyclable catalyst.


  • A trisubstituted pyrazole derivative reduces DMBA-induced mammary tumor growth in rats by inhibiting estrogen receptor-α expression

    by Hanumappa Ananda, Kothanahally S. Sharath Kumar, Muddenahalli S. Sudhanva, Shobith Rangappa, Kanchugarakoppal S. Rangappa

    Aberrant expression of estrogen receptor alpha (ER-α) is observed in many pathological complications like breast cancer, endometrial cancer, and in osteoporosis. ER-α plays a vital role in the initiation and progression of breast cancer and confers chemo and radioresistance to the cancer cells by upregulating expression of anti-apoptotic proteins. The synthetic pyrazole derivative 3-(1-(4-bromophenyl)-5-phenyl-1H-pyrazol-3-yl)pyridine (compound 5d) displays significant cytotoxicity against mammary carcinoma cells. Molecular docking studies revealed that compound 5d binds to ligand binding domain of (ER-α). In vivo studies were carried out to investigate ER-α expression by immunohistochemistry and quantitative RT-PCR, which revealed reduction of ER-α in tumor cells upon treatment with compound 5d indicating its ER-α antagonistic effect. Our study ascertains compound 5d as a potent inhibitor of mammary carcinoma cells.


  • Novel oxolane derivative DMTD mitigates high glucose-induced erythrocyte apoptosis by regulating oxidative stress

    by Swamy Jagadish, Mahadevappa Hemshekhar, Somanathapura K. NaveenKumar, Kothanahally S. Sharath Kumar, Mahalingam S. Sundaram, Basappa, Kesturu S. Girish, Kanchugarakoppal S. Rangappa


  • Regioselective synthesis and biological studies of novel 1-aryl-3, 5-bis (het) aryl pyrazole derivatives as potential antiproliferative agents

    by Hanumappa Ananda, Kothanahally S. Sharath Kumar, Mayilaadumveettil Nishana, Mahesh Hegde, Mrinal Srivastava, Raghava Byregowda, Bibha Choudhary, Sathees C. Raghavan, Kanchugarakoppal S. Rangappa

    Pyrazole moiety represents an important category of heterocyclic compound in pharmaceutical and medicinal chemistry. The novel 1-aryl-3, 5-bis (het) aryl pyrazole derivatives were synthesized with complementary regioselectivity. The chemical structures were confirmed by IR, 1H NMR, 13C NMR, and mass spectral analysis. The chemical entities were screened in various cancer cell lines to assess their cell viability activity. Results showed that the compound 3-(1-(4-bromophenyl)-5-phenyl-1H-pyrazol-3-yl) pyridine (5d) possessed maximum cytotoxic effect against breast cancer and leukemic cells. The cytotoxicity was confirmed by live–dead cell assay and cell cycle analysis. Mitochondrial membrane potential, Annexin V-FITC staining, DNA fragmentation, Hoechst staining, and western blot assays revealed the ability of compound 5d to induce cell death by activating apoptosis in cancer cells. Thus, the present study demonstrates that compound 5d could be an attractive chemical entity for the development of small molecule inhibitors for treatment of leukemia and breast cancer.


  • Open Access

    1-(2′-Ethoxy-4′-fluoro-[1,1′-biphenyl]-4-yl)-4-phenyl-1H-1,2,3-triazole

    by Maryam Gilandoust, S. Naveen, K. B. Harsha, N. K. Lokanath, K. S. Rangappa

    In the title compound, C22H18FN3O, the triazole ring is planar. The plane of the triazole ring makes dihedral angles of 19.31 (10), 20.52 (10) and 39.82 (9)° with the planes of the benzene rings, indicating the overall nonplanarity of the molecule. No classical hydrogen bonds were observed in the structure.


  • Combinatorial Study of a Novel Poly (ADP-ribose) Polymerase Inhibitor and an HDAC Inhibitor, SAHA, in Leukemic Cell Lines

    by Mahesh Hegde, Kempegowda Mantelingu, Monica Pandey, Chottanahalli S. Pavankumar, Kanchugarakoppal S. Rangappa, Sathees C. Raghavan

    Background Cancer is a multifactorial disease, which makes it difficult to cure. Since more than one defective cellular component is often involved during oncogenesis, combination therapy is gaining prominence in the field of cancer therapeutics. Objective The purpose of this study was to investigate the combinatorial effects of a novel PARP inhibitor, P10, and HDAC inhibitor, SAHA, in leukemic cells. Methods Combinatorial effects of P10 and SAHA were tested using propidium iodide staining in different leukemic cells. Further, flowcytometry-based assays such as calcein-AM/ethidium homodimer staining, annexin-FITC/PI staining, and JC-1 staining were carried out to elucidate the mechanism of cell death. In addition, cell-cycle analysis, immunocytochemistry studies, and western blotting analysis were conducted to check the combinatorial effect in Nalm6 cells. Results Propidium iodide staining showed that P10 in combination with SAHA induced cell death in Nalm6 cells, in which PARP expression and activity is high with a combination index of 65 % cells. Importantly, combinatorial treatment induced S phase arrest in 40-45 % cells due to DNA damage and plausible replicative stress. Finally, we demonstrated that treatment with P10 led to DNA strand breaks, which were further potentiated by SAHA (p < 0.01), leading to activation of apoptosis and increased cell death in PARP-positive leukemic cells. Conclusions Our study reveals that coadministration of PARP inhibitor with SAHA could be used as a combination therapy against leukemic cells that possess high levels of intrinsic PARP activity.


  • Open Access

    3-(1-{[1-(4-Bromophenyl)-1H-1,2,3-triazol-4-yl]methyl}piperidin-4-yl)-6-fluoro-1,2-benzoxazole hemihydrate

    by N. Ashwini, S. Naveen, K. S. Rakesh, N. K. Lokanath, K. S. Rangappa

    The title compound, C21H19BrFN5O·0.5H2O, crystallizes as a hemihydrate with the water molecule located on a twofold rotation axis. The piperidine ring has a chair conformation, whereas the triazole and the benzisoxazole rings are planar (r.m.s. deviations = 0.006 and 0.009 Å, respectively). The N—C and C—C bonds connecting the triazole and benzisoxazole rings, respectively, to the piperidine ring lie in equatorial positions. In the crystal, molecules related by a twofold rotation axis are linkedviaO—H...N hydrogen bonds involving the water molecule and a pair of C—H...N hydrogen bonds forming dimers. The dimers are linkedviaa pair of C—H...F hydrogen bonds leading to the formation of chains propagating along [101].


  • Novel PARP inhibitors sensitize human leukemic cells in an endogenous PARP activity dependent manner

    by Mahesh Hegde, Kempegowda Mantelingu, Hassan A. Swarup, Chottanahalli S. Pavankumar, Imteyaz Qamar, Sathees C. Raghavan, Kanchugarakoppal S. Rangappa

    Poly(ADP-ribose) polymerase (PARP) is a critical nuclear enzyme which safeguards genome stability from genotoxic insults and helps in DNA repair. Inhibition of PARP results in sustained DNA damage in cancer cells. PARP inhibitors are known to play an important role in chemotherapy as single agents in many DNA repair pathway deficient tumor cells or in combination with several other chemotherapeutic agents. In the present study, we synthesize and characterize novel pyridazine derivatives, and evaluate their potential for use as PARP inhibitors. Results show that pyridazine derivatives inhibited the PARP1 enzymatic activity at the nanomolar range and showed anti-proliferative activity in leukemic cells. Interestingly, human leukemic cell line, Nalm6, in which PARP1 and PARP2 expression as well as intrinsic PARP activity are high, showed significant sensitivity for the novel inhibitors compared to other leukemic cells. Among the inhibitors, P10 showed maximum inhibition of intrinsic PARP activity and inhibited cell proliferation in Nalm6 cells. Besides P10 also showed maximum inhibition against purified PARP1 protein, which was comparable to olaparib in our assays. Newly synthesized compounds also showed remarkable DNA trapping ability, which is a signature feature of many PARP inhibitors. Importantly, P10 also induced late S and G2/M arrest in Nalm6 cells, indicating accumulation of DNA damage. Therefore, we identify P10 as a potential PARP inhibitor, which can be developed as a chemotherapeutic agent.


  • A novel benzimidazole derivative binds to the DNA minor groove and induces apoptosis in leukemic cells

    by Mahesh Hegde, Kothanahally S. Sharath Kumar, Elizabeth Thomas, Hanumappa Ananda, Sathees C. Raghavan, Kanchugarakoppal S. Rangappa

    DNA minor groove binders are an important class of chemotherapeutic agents. These small molecule inhibitors interfere with various cellular processes like DNA replication and transcription. Several benzimidazole derivatives showed affinity towards the DNA minor groove. In this study we show the synthesis and biological studies of a novel benzimidazole derivative (MH1), that inhibits topoisomerase II activity and in vitro transcription. UV-visible and fluorescence spectroscopic methods in conjunction with Hoechst displacement assay demonstrate that MH1 binds to DNA at the minor groove. Cytotoxic studies showed that leukemic cells are more sensitive to MH1 compared to cancer cells of epithelial origin. Further, we find that MH1 treatment leads to cell cycle arrest at G2/M, at early time points in Molt4 cells. Finally multiple cellular assays demonstrate that MH1 treatment leads to reduction in MMP, induction of apoptosis by activating CASPASE 9 and CASPASE 3. Thus our study shows MH1, a novel DNA minor groove binder, induces cytotoxicity efficiently in leukemic cells by activating the intrinsic pathway of apoptosis.


  • Open Access

    SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool

    by Dhanasekaran Karthigeyan, Soumik Siddhanta, Annavarapu Hari Kishore, Sathya S. R. R. Perumal, Hans Ågren, Surabhi Sudevan, Akshay V. Bhat, Karanam Balasubramanyam, Rangappa Kanchugarakoppal Subbegowda, Tapas K. Kundu, et al.

    Significance: Surface-enhanced Raman spectroscopy along with molecular dynamics simulation is shown to be a useful tool for understanding drug binding to therapeutic proteins. Herein, the selective binding of felodipine to human Aurora A kinase is employed as a test system to demonstrate this powerful technique. Preliminary knowledge of the protein structure makes this approach robust for drug discovery.